Friday, April 4, 2025 4/4/2025

NRG Oncology Network Group Operations Center

Award Number: U10CA180868
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

NRG Oncology Network Group Operations Center - NRG Overall Component Abstract NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-specific malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP- supported NRG trials open for enrollment during this period, representing 34% of the open NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of African descent and 8.0% as Latino or Hispanic. There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published abstracts during this period, of which at least 52 contain practice-changing or practice-defining observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site committees, all with internationally recognized multi-disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	11	11/20/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $8,236,845 )
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	005	11	8/28/2024	NON-COMPETING CONTINUATION	$2,398,415
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	003	11	4/16/2024	NON-COMPETING CONTINUATION	$787,548
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	004	11	5/6/2024	SUPPLEMENT FOR EXPANSION	$415,295
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	006	11	8/29/2024	NON-COMPETING CONTINUATION	$0
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	007	11	9/16/2024	SUPPLEMENT FOR EXPANSION	$691,599
2024	2024	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	11	3/25/2024	NON-COMPETING CONTINUATION	$10,380,670
2024	2018	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	5	10/1/2023	SUPPLEMENT FOR EXPANSION	-$5,693,671
2024	2018	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	5	10/1/2023	SUPPLEMENT FOR EXPANSION	-$743,011
														Subtotal = $8,236,845

Issue Date FY: 2023 ( Subtotal = $23,044,783 )
2023	2023	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	007	10	8/17/2023	NON-COMPETING CONTINUATION	$1,757,267
2023	2023	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	005	10	4/28/2023	SUPPLEMENT FOR EXPANSION	$772,082
2023	2023	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	004	10	3/28/2023	NON-COMPETING CONTINUATION	$12,662,113
2023	2023	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	008	10	8/25/2023	SUPPLEMENT FOR EXPANSION	$322,489
2023	2023	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	006	10	8/3/2023	NON-COMPETING CONTINUATION	$0
2023	2023	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	9	1/11/2023	SUPPLEMENT FOR EXPANSION	$1,094,150
2023	2022	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	003	9	2/27/2023	NON-COMPETING CONTINUATION	$0
2023	2018	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	5	10/28/2022	SUPPLEMENT FOR EXPANSION	$743,011
2023	2018	NRG ONCOLOGY FOUNDATION INC	1600 JOHN F KENNEDY BLVD	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	5	10/28/2022	NON-COMPETING CONTINUATION	$5,693,671
														Subtotal = $23,044,783

Issue Date FY: 2022 ( Subtotal = $13,042,248 )
2022	2022	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	9	4/13/2022	NON-COMPETING CONTINUATION	$7,348,391
2022	2022	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	003	9	7/22/2022	SUPPLEMENT FOR EXPANSION	$1,076,160
2022	2022	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	005	9	8/18/2022	NON-COMPETING CONTINUATION	$4,980,320
2022	2022	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	004	9	8/16/2022	NON-COMPETING CONTINUATION	-$556,698
2022	2022	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	006	9	8/29/2022	SUPPLEMENT FOR EXPANSION	$194,075
2022	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	8	11/22/2021	NON-COMPETING CONTINUATION	$0
2022	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	8	12/20/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $13,042,248

Issue Date FY: 2021 ( Subtotal = $15,069,130 )
2021	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	004	8	4/16/2021	SUPPLEMENT FOR EXPANSION	$946,881
2021	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	003	8	3/26/2021	NON-COMPETING CONTINUATION	$12,602,316
2021	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	006	8	8/18/2021	SUPPLEMENT FOR EXPANSION	$302,488
2021	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	005	8	4/21/2021	SUPPLEMENT FOR EXPANSION	$0
2021	2021	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	007	8	9/8/2021	NON-COMPETING CONTINUATION	$1,217,445
2021	2020	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	7	12/1/2020	NON-COMPETING CONTINUATION	$0
2021	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	6	11/24/2020	COMPETING CONTINUATION	-$802,506
2021	2018	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	5	11/24/2020	NON-COMPETING CONTINUATION	$802,506
														Subtotal = $15,069,130

Issue Date FY: 2020 ( Subtotal = $16,486,136 )
2020	2020	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	7	8/26/2020	SUPPLEMENT FOR EXPANSION	$140,205
2020	2020	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	005	7	9/21/2020	NON-COMPETING CONTINUATION	$712,867
2020	2020	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	000	7	5/18/2020	NON-COMPETING CONTINUATION	$14,059,246
2020	2020	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	7	6/15/2020	SUPPLEMENT FOR EXPANSION	$1,573,818
2020	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	004	6	8/26/2020	COMPETING CONTINUATION	$401,253
2020	2018	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	003	5	8/26/2020	NON-COMPETING CONTINUATION	-$401,253
														Subtotal = $16,486,136

Issue Date FY: 2019 ( Subtotal = $13,312,787 ) (Continued on the next page)
2019	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	006	6	7/3/2019	SUPPLEMENT FOR EXPANSION	$926,612
2019	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	002	6	5/10/2019	COMPETING CONTINUATION	-$292,521
2019	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	007	6	8/27/2019	COMPETING CONTINUATION	$117,993
2019	2019	NRG ONCOLOGY FOUNDATION, INC.	1600 JOHN F KENNEDY BLVD STE 1020	PHILADELPHIA	PA	19103	PHILADELPHIA	USA	Cancer Treatment Research	001	6	4/16/2019	COMPETING CONTINUATION	$12,056,992
Grand Total All Awards = $165,137,911

Page 1 of 2 (82 items)12

Top

All Categories

About

Search

Reports

Data Submission

Award Information

NRG Oncology Network Group Operations Center

Award Number: U10CA180868

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer